Summary of the HTA, funding and innovation payment landscape for endocrine devices in Europe

07

Oct 2019

MTRC has developed three reports on the key market access topics, including innovation funding, health technology assessment and funding frameworks for medical devices. These reports help to understand the relevance of these frameworks to certain types of medical technologies, including endocrine technologies.

Did you know that:

  • There were 11 health technology assessments of endocrine technologies in 2018 in Europe;
  • These assessments were published only in 4 EU countries;
  • Only 1 assessment was published by the regional HTA bodies, the remaining were published by the national organizations;
  • There were 10 funding decisions about endocrine technologies published in 2 EU with established funding frameworks countries for all time periods;
  • In 100% of the cases, funding decisions were positive in relation to endocrine technologies;

By accessing one or several of our syndicated reports you can:

  • Understand the relevance of topics of innovation funding, health technology assessment and funding frameworks in the endocrine field;
  • Understand, which countries are more active with HTA, funding and innovation funding for endocrine devices;
  • Understand, what types of technologies typically triggers HTA or review by the funding authorities / decision-makers;
  • Understand, what endocrine technologies got positive and negative funding decisions;
  • Develop fact-based market access strategies for your portfolio of devices;
  • Prioritize markets, based on the solid information about HTA and reimbursement activity for your type of product.

You can get access either to the full reports or limited to the topic of endocrine devices. Download sample pages of the reports via the links provided above.

Contact us at info@mtrconsult.com to request a quote or get more information.

The latest related news

25

Mar 2022

On March 4, 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced three projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a new minimally invasive endoscopy-guided surgery in patients with spontaneous cerebral hemorrhage, oral immunotherapy in children to cure a food allergy and cutting the diaphragm band in chronic abdominal complaints.

Read more

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

21

Mar 2022

The NHS Insights Prioritisation Programme (NIPP) is commissioned by the NHS Accelerated Access Collaborative (AAC) and the National Institute for Health Research (NIHR). It is designed to accelerate the evaluation and implementation of innovation that supports post-pandemic ways of working, builds service resilience, and delivers benefits to patients. Fourteen projects have been funded and have now commenced activity that will be ongoing until March 2023.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more